|
1
|
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.
|
Nat Med
|
2008
|
11.49
|
|
2
|
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
|
J Clin Invest
|
2011
|
6.38
|
|
3
|
Inducible apoptosis as a safety switch for adoptive cell therapy.
|
N Engl J Med
|
2011
|
6.14
|
|
4
|
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.
|
Nat Med
|
2006
|
4.42
|
|
5
|
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes.
|
Blood
|
2004
|
4.01
|
|
6
|
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.
|
Blood
|
2007
|
3.94
|
|
7
|
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.
|
Blood
|
2011
|
3.82
|
|
8
|
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
|
J Clin Oncol
|
2013
|
3.65
|
|
9
|
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
|
J Exp Med
|
2004
|
3.57
|
|
10
|
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.
|
Blood
|
2009
|
3.27
|
|
11
|
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.
|
Mol Ther
|
2005
|
3.18
|
|
12
|
An inducible caspase 9 safety switch for T-cell therapy.
|
Blood
|
2005
|
2.93
|
|
13
|
CARs on track in the clinic.
|
Mol Ther
|
2011
|
2.86
|
|
14
|
Post-transplant lymphoproliferative disorders.
|
Annu Rev Med
|
2005
|
2.82
|
|
15
|
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.
|
Blood
|
2009
|
2.79
|
|
16
|
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.
|
Blood
|
2006
|
2.68
|
|
17
|
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
|
Blood
|
2007
|
2.50
|
|
18
|
Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.
|
Blood
|
2009
|
2.47
|
|
19
|
Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2007
|
2.33
|
|
20
|
Adoptive T cell therapy of cancer.
|
Curr Opin Immunol
|
2010
|
2.13
|
|
21
|
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.
|
Blood
|
2013
|
2.13
|
|
22
|
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.
|
Blood
|
2007
|
2.11
|
|
23
|
Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects.
|
Blood
|
2010
|
2.06
|
|
24
|
Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.
|
Blood
|
2002
|
1.98
|
|
25
|
Impending challenges in the hematopoietic stem cell transplantation physician workforce.
|
Biol Blood Marrow Transplant
|
2009
|
1.97
|
|
26
|
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.
|
Blood
|
2013
|
1.95
|
|
27
|
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.
|
Blood
|
2006
|
1.93
|
|
28
|
Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
|
Blood
|
2002
|
1.89
|
|
29
|
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).
|
J Immunother
|
2010
|
1.81
|
|
30
|
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs).
|
Blood
|
2006
|
1.75
|
|
31
|
Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes.
|
J Exp Med
|
2004
|
1.72
|
|
32
|
Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections.
|
Mol Ther
|
2012
|
1.72
|
|
33
|
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.
|
Blood
|
2011
|
1.72
|
|
34
|
Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy.
|
J Virol
|
2007
|
1.70
|
|
35
|
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.
|
Clin Cancer Res
|
2011
|
1.70
|
|
36
|
HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.
|
Clin Cancer Res
|
2010
|
1.65
|
|
37
|
Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma.
|
Leuk Lymphoma
|
2010
|
1.64
|
|
38
|
Regression of experimental medulloblastoma following transfer of HER2-specific T cells.
|
Cancer Res
|
2007
|
1.58
|
|
39
|
Prompt versus preemptive intervention for EBV lymphoproliferative disease.
|
Blood
|
2004
|
1.57
|
|
40
|
Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses.
|
Blood
|
2003
|
1.55
|
|
41
|
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.
|
Blood
|
2008
|
1.52
|
|
42
|
Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.
|
J Immunother
|
2010
|
1.50
|
|
43
|
Safer CARS.
|
Mol Ther
|
2010
|
1.46
|
|
44
|
In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
|
Leuk Lymphoma
|
2006
|
1.46
|
|
45
|
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.
|
Blood
|
2010
|
1.44
|
|
46
|
Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.
|
J Immunol
|
2005
|
1.42
|
|
47
|
Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection.
|
Blood
|
2002
|
1.40
|
|
48
|
Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.
|
Mol Ther
|
2009
|
1.40
|
|
49
|
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506).
|
Blood
|
2009
|
1.39
|
|
50
|
Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.
|
Mol Ther
|
2013
|
1.38
|
|
51
|
Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy.
|
J Immunother
|
2003
|
1.37
|
|
52
|
T-cell therapy in the treatment of post-transplant lymphoproliferative disease.
|
Nat Rev Clin Oncol
|
2012
|
1.36
|
|
53
|
Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients.
|
Am J Transplant
|
2005
|
1.36
|
|
54
|
Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.
|
Mol Ther
|
2009
|
1.36
|
|
55
|
Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen.
|
Biol Blood Marrow Transplant
|
2008
|
1.35
|
|
56
|
The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
|
J Immunother
|
2004
|
1.35
|
|
57
|
Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7.
|
Mol Ther
|
2009
|
1.35
|
|
58
|
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
|
Blood
|
2008
|
1.33
|
|
59
|
Adoptive immunotherapy for EBV-associated malignancies.
|
Leuk Lymphoma
|
2005
|
1.30
|
|
60
|
High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.
|
Blood
|
2011
|
1.29
|
|
61
|
Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor.
|
J Immunother
|
2008
|
1.25
|
|
62
|
Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.
|
Mol Ther
|
2013
|
1.25
|
|
63
|
An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies.
|
Stem Cells
|
2010
|
1.23
|
|
64
|
Preparing for growth: current capacity and challenges in hematopoietic stem cell transplantation programs.
|
Biol Blood Marrow Transplant
|
2010
|
1.20
|
|
65
|
Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia.
|
Biol Blood Marrow Transplant
|
2006
|
1.18
|
|
66
|
Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.
|
Clin Cancer Res
|
2014
|
1.17
|
|
67
|
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy.
|
Mol Ther Nucleic Acids
|
2013
|
1.16
|
|
68
|
Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells.
|
Cancer Res
|
2002
|
1.15
|
|
69
|
Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease.
|
Am J Transplant
|
2005
|
1.13
|
|
70
|
Genetic modification of T cells.
|
Biol Blood Marrow Transplant
|
2011
|
1.10
|
|
71
|
Adoptive immunotherapy for posttransplantation viral infections.
|
Biol Blood Marrow Transplant
|
2004
|
1.07
|
|
72
|
Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.
|
Clin Cancer Res
|
2012
|
1.06
|
|
73
|
Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals.
|
J Immunol
|
2002
|
1.06
|
|
74
|
Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy.
|
Biol Blood Marrow Transplant
|
2003
|
1.05
|
|
75
|
Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.
|
J Immunother
|
2012
|
1.04
|
|
76
|
A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
|
Cancer Gene Ther
|
2004
|
1.02
|
|
77
|
A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease.
|
Blood
|
2006
|
1.02
|
|
78
|
Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation.
|
Blood
|
2012
|
1.00
|
|
79
|
Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation.
|
Cytotherapy
|
2011
|
0.98
|
|
80
|
Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.
|
Cytotherapy
|
2012
|
0.98
|
|
81
|
Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.
|
Mol Ther
|
2011
|
0.97
|
|
82
|
Ex vivo gene transfer for improved adoptive immunotherapy of cancer.
|
Hum Mol Genet
|
2011
|
0.97
|
|
83
|
Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment.
|
PLoS One
|
2011
|
0.97
|
|
84
|
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.
|
Blood
|
2005
|
0.96
|
|
85
|
Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor.
|
J Immunother
|
2006
|
0.95
|
|
86
|
Cytotoxic T lymphocytes as immune-therapy in haematological practice.
|
Br J Haematol
|
2008
|
0.95
|
|
87
|
Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?
|
Mol Ther
|
2012
|
0.94
|
|
88
|
Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience.
|
Cytotherapy
|
2010
|
0.94
|
|
89
|
Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease.
|
J Allergy Clin Immunol
|
2011
|
0.94
|
|
90
|
Adoptive T-cell transfer in cancer immunotherapy.
|
Immunol Cell Biol
|
2006
|
0.93
|
|
91
|
Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.
|
Br J Haematol
|
2011
|
0.93
|
|
92
|
Survivin-specific T cell receptor targets tumor but not T cells.
|
J Clin Invest
|
2014
|
0.91
|
|
93
|
Antiviral T-cell therapy.
|
Immunol Rev
|
2014
|
0.91
|
|
94
|
A single institution experience with pediatric nasopharyngeal carcinoma: high incidence of toxicity associated with platinum-based chemotherapy plus IMRT.
|
J Pediatr Hematol Oncol
|
2007
|
0.91
|
|
95
|
Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.
|
J Immunother
|
2013
|
0.90
|
|
96
|
Treatment of Epstein-Barr virus-associated malignancies with specific T cells.
|
Adv Cancer Res
|
2002
|
0.90
|
|
97
|
The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia.
|
Biol Blood Marrow Transplant
|
2010
|
0.90
|
|
98
|
Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection.
|
Clin Transplant
|
2006
|
0.89
|
|
99
|
Immunotherapy for Epstein-Barr virus-associated cancers in children.
|
Oncologist
|
2003
|
0.89
|
|
100
|
Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease.
|
Haematologica
|
2012
|
0.89
|
|
101
|
Immunotherapy for post-transplant lymphoproliferative disease.
|
Br J Haematol
|
2002
|
0.89
|
|
102
|
Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
|
Recent Results Cancer Res
|
2002
|
0.88
|
|
103
|
Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.
|
J Immunother
|
2014
|
0.88
|
|
104
|
Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.
|
Biol Blood Marrow Transplant
|
2008
|
0.87
|
|
105
|
Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy.
|
J Immunother
|
2008
|
0.87
|
|
106
|
Posttransplant lymphoproliferative disease following liver transplantation.
|
Curr Opin Organ Transplant
|
2011
|
0.87
|
|
107
|
Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man.
|
Ann N Y Acad Sci
|
2003
|
0.87
|
|
108
|
Immunotherapy targeting EBV-expressing lymphoproliferative diseases.
|
Best Pract Res Clin Haematol
|
2008
|
0.86
|
|
109
|
Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients.
|
Transplantation
|
2013
|
0.86
|
|
110
|
Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
|
Clin Transplant
|
2006
|
0.86
|
|
111
|
Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.
|
J Clin Invest
|
2016
|
0.85
|
|
112
|
Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia.
|
Cancer Treat Rev
|
2003
|
0.84
|
|
113
|
Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease.
|
Acta Haematol
|
2003
|
0.84
|
|
114
|
Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children.
|
Biol Blood Marrow Transplant
|
2005
|
0.83
|
|
115
|
Children with acute leukemia: a comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation.
|
Pediatr Blood Cancer
|
2011
|
0.83
|
|
116
|
Intravenous Cidofovir therapy for disseminated adenovirus in a pediatric liver transplant recipient.
|
Transplantation
|
2002
|
0.82
|
|
117
|
Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes.
|
Transplantation
|
2004
|
0.82
|
|
118
|
Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2002
|
0.82
|
|
119
|
Computer-assisted quantitative evaluation of therapeutic responses for lymphoma using serial PET/CT imaging.
|
Acad Radiol
|
2010
|
0.81
|
|
120
|
Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma.
|
Clin Lymphoma Myeloma
|
2006
|
0.80
|
|
121
|
T lymphocytes targeting native receptors.
|
Immunol Rev
|
2014
|
0.80
|
|
122
|
T cell therapy in allogeneic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2008
|
0.80
|
|
123
|
Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression.
|
Mol Cancer
|
2009
|
0.80
|
|
124
|
T-cell-based therapies for malignancy and infection in childhood.
|
Pediatr Clin North Am
|
2010
|
0.80
|
|
125
|
Immunotherapy for epstein-barr virus-related lymphomas.
|
Mediterr J Hematol Infect Dis
|
2009
|
0.79
|
|
126
|
Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant.
|
Curr Opin Hematol
|
2014
|
0.78
|
|
127
|
Viral lymphomagenesis.
|
Curr Opin Hematol
|
2006
|
0.78
|
|
128
|
Transfusion-related acute lung injury (TRALI) following allogeneic stem cell transplant for acute myeloid leukemia.
|
Am J Hematol
|
2004
|
0.78
|
|
129
|
New ISSCR guidelines: clinical translation of stem cell research.
|
Lancet
|
2016
|
0.77
|
|
130
|
Immunotherapy to reconstitute immunity to DNA viruses.
|
Semin Hematol
|
2002
|
0.77
|
|
131
|
Guidance for developing phase II cell therapy trial proposals for consideration by the Blood and Marrow Transplant Clinical Trials Network.
|
Biol Blood Marrow Transplant
|
2010
|
0.76
|
|
132
|
Adoptive cellular therapy with T cells specific for EBV-derived tumor antigens.
|
Update Cancer Ther
|
2008
|
0.75
|
|
133
|
Commentary on journal of immunotherapy paper by melenhorst et al.
|
J Immunother
|
2006
|
0.75
|
|
134
|
Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection.
|
Pediatr Blood Cancer
|
2011
|
0.75
|
|
135
|
Genetically engineered T-cells for adoptive immunotherapy.
|
Curr Opin Mol Ther
|
2002
|
0.75
|
|
136
|
Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease.
|
Acta Haematol
|
2003
|
0.75
|
|
137
|
New approaches in alternative donor transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
0.75
|